SG11201507241UA - Cyclosporine a-steroid conjugates - Google Patents

Cyclosporine a-steroid conjugates

Info

Publication number
SG11201507241UA
SG11201507241UA SG11201507241UA SG11201507241UA SG11201507241UA SG 11201507241U A SG11201507241U A SG 11201507241UA SG 11201507241U A SG11201507241U A SG 11201507241UA SG 11201507241U A SG11201507241U A SG 11201507241UA SG 11201507241U A SG11201507241U A SG 11201507241UA
Authority
SG
Singapore
Prior art keywords
cyclosporine
steroid conjugates
steroid
conjugates
Prior art date
Application number
SG11201507241UA
Other languages
English (en)
Inventor
Santosh C Sinha
Ken Chow
Liming Wang
Brandon D Swift
Mayssa Attar
Michael E Garst
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50382692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201507241U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of SG11201507241UA publication Critical patent/SG11201507241UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
SG11201507241UA 2013-03-08 2014-03-06 Cyclosporine a-steroid conjugates SG11201507241UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775216P 2013-03-08 2013-03-08
PCT/US2014/021283 WO2014138425A1 (en) 2013-03-08 2014-03-06 Cyclosporine a-steroid conjugates

Publications (1)

Publication Number Publication Date
SG11201507241UA true SG11201507241UA (en) 2015-10-29

Family

ID=50382692

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507241UA SG11201507241UA (en) 2013-03-08 2014-03-06 Cyclosporine a-steroid conjugates

Country Status (16)

Country Link
US (4) US20140256694A1 (zh)
EP (2) EP2964268A1 (zh)
JP (1) JP2016510754A (zh)
KR (1) KR20150125663A (zh)
CN (1) CN105025929A (zh)
AR (2) AR095072A1 (zh)
AU (1) AU2014225637A1 (zh)
BR (1) BR112015021388A2 (zh)
CA (1) CA2899500A1 (zh)
CL (1) CL2015002210A1 (zh)
IL (1) IL240920A0 (zh)
PH (1) PH12015501857A1 (zh)
RU (1) RU2015135145A (zh)
SG (1) SG11201507241UA (zh)
TW (2) TW201511758A (zh)
WO (4) WO2014138359A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138359A1 (en) 2013-03-08 2014-09-12 Allergan, Inc. Steroid antibiotic conjugates
MX2015011948A (es) 2013-03-08 2015-12-09 Allergan Inc Antibioticos conjugados directamente relacionados con farmacos esteroides.
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
EP3600338A4 (en) 2017-03-28 2020-10-28 The University of North Carolina at Chapel Hill NITRIC OXIDE RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES
CA3087898A1 (en) 2018-02-02 2019-08-08 Ripple Therapeutics Corporation Glass formulations comprising steroid dimers and uses thereof
WO2019173539A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3840769A4 (en) * 2018-08-22 2022-06-22 Bacainn Biotherapeutics, Ltd. CYCLOSPORINE COMPOSITIONS AND METHODS OF USE
WO2020047496A1 (en) * 2018-08-31 2020-03-05 Aerie Pharmaceuticals, Inc. Isoquinoline-steroid conjugates and uses thereof
JP2022516461A (ja) 2018-12-28 2022-02-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 一酸化窒素放出抗菌性ポリマーおよびそれから製造された足場、ならびにそれに関する方法
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
WO2023079362A1 (en) * 2021-11-03 2023-05-11 Ripple Therapeutics Corporation Processable compositions and use for the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2999102A (en) * 1959-10-14 1961-09-05 Thomae Gmbh Dr K Bis-(steroid-21)-dicarboxylic acid esters
US3147183A (en) * 1962-04-16 1964-09-01 Boehringer Sohn Ingelheim Bis-(steroid-21)-dicarboxylic acid esters
US3916002A (en) * 1973-12-17 1975-10-28 Taubert Hans Dieter Oligomeric steroid esters, process for their production, and therapeutic compositions containing the same
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
WO1994016330A1 (en) 1993-01-06 1994-07-21 Beckman Instruments, Inc. Method for making a preconjugate
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
CA2136803A1 (en) 1993-12-22 1995-06-23 Kazumi Ogata Steroid derivatives
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
ATE267798T1 (de) 1994-01-28 2004-06-15 Univ Kentucky Res Found Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
US6350422B1 (en) 1998-09-21 2002-02-26 Phillips Petroleum Company Sorbent compositions
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
WO2001005819A1 (en) 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6306842B1 (en) 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
IL158527A0 (en) * 2001-04-26 2004-05-12 Control Delivery Sys Inc Sustained release drug delivery system containing codrugs
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
WO2003031441A1 (en) 2001-10-04 2003-04-17 Morphochen Aktiengesellschaft Für Kombinatorische Chemie Multiple action compounds
AUPR879601A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
WO2003043657A1 (en) 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs
EP1603512A2 (en) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Novel cyclosporins
HRP20030324A2 (en) 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
DE602004014361D1 (de) 2003-04-30 2008-07-24 Morphochem Ag Komb Chemie Verwendung von oxazolidinon-chinolin-hybrid-antibiotika zur behandlung von anthrax und anderen infektionen
US20050008695A1 (en) * 2003-05-21 2005-01-13 Control Delivery Systems, Inc. Compositions and methods for delivering a biologically active agent
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
WO2008069824A2 (en) 2006-02-27 2008-06-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for transport of molecules with enhanced release properties across biological barriers
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
ITMI20080382A1 (it) 2008-03-07 2009-09-08 Ctg Pharma S R L Composizioni farmaceutiche oculari
JP5661035B2 (ja) 2008-07-10 2015-01-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼および皮膚の疾患および症状の治療用のシクロスポリン誘導体
MX2008014515A (es) * 2008-09-09 2010-04-29 Allergan Inc Suspension oftalmica para uso ocular.
US8809286B2 (en) * 2009-03-31 2014-08-19 Technion Research & Development Foundation Limited Conjugated antimicrobial agents
JP2012528163A (ja) 2009-05-27 2012-11-12 アラーガン、インコーポレイテッド 炎症性疾患および状態を処置するためのシクロスポリン誘導体
AU2011316689B2 (en) 2010-10-12 2016-07-14 Allergan, Inc. Cyclosporin analogs
CA2814192A1 (en) 2010-10-12 2012-04-19 Allergan, Inc. Cyclosporin analogs
MX2014003260A (es) * 2011-09-16 2014-09-08 Davidson Lopez Llc Esteroides de plantas y usos de los mismos.
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
WO2014138359A1 (en) 2013-03-08 2014-09-12 Allergan, Inc. Steroid antibiotic conjugates
MX2015011948A (es) 2013-03-08 2015-12-09 Allergan Inc Antibioticos conjugados directamente relacionados con farmacos esteroides.
WO2014138343A1 (en) 2013-03-08 2014-09-12 Allergan, Inc. Antibiotic conjugates with nonsteroidal anti-inflammatory drugs
AU2014225682A1 (en) 2013-03-08 2015-09-24 Allergan, Inc. Antibiotic conjugates linked with steroid drugs

Also Published As

Publication number Publication date
WO2014138359A1 (en) 2014-09-12
KR20150125663A (ko) 2015-11-09
TW201511758A (zh) 2015-04-01
US9402913B2 (en) 2016-08-02
IL240920A0 (en) 2015-10-29
WO2014138403A1 (en) 2014-09-12
WO2014138437A1 (en) 2014-09-12
CA2899500A1 (en) 2014-09-12
WO2014138425A1 (en) 2014-09-12
US20140256696A1 (en) 2014-09-11
BR112015021388A2 (pt) 2017-07-18
TW201511768A (zh) 2015-04-01
EP2964268A1 (en) 2016-01-13
AU2014225637A1 (en) 2015-09-03
PH12015501857A1 (en) 2015-12-07
AR095073A1 (es) 2015-09-16
CL2015002210A1 (es) 2016-01-22
RU2015135145A (ru) 2017-04-13
AR095072A1 (es) 2015-09-16
US20140256694A1 (en) 2014-09-11
CN105025929A (zh) 2015-11-04
US20140256658A1 (en) 2014-09-11
US20140256651A1 (en) 2014-09-11
JP2016510754A (ja) 2016-04-11
EP2964269A1 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
IL244816A0 (en) Protein-polymer-drug conjugates
IL245009A0 (en) Attach a drug from a protein and a polymer
HK1210547A1 (zh) 無電阻器預充電
EP2970511A4 (en) INSULIN CONJUGATES incretin
IL240920A0 (en) Cyclosporine a-steroid conjugates
EP2961302A4 (en) MIXING SYSTEM
HK1219427A1 (zh) 複合物
SG11201605260VA (en) Var2csa-drug conjugates
EP3056613C0 (en) SHOVEL
EP2989885A4 (en) COMBINE
EP3042608A4 (en) SEAT
EP2968381A4 (en) MEDICAMENT CONJUGATES-SUGAR BINDING SEQUENCE
GB2514888B (en) Seat structure
GB201414806D0 (en) Cyclosporin conjugates
GB2526466B (en) Blend
GB201314411D0 (en) Peptide conjugates
GB2519832B (en) Cyclodextrin
EP3032112A4 (en) SHOVEL
SG11201508345TA (en) Nanoprobe-based genetic testing
GB201305118D0 (en) Blends
GB201306882D0 (en) Oligosaccharide
GB201410767D0 (en) Connection arrangement
GB201310268D0 (en) Seating
GB201303681D0 (en) Cyclosporin derivatives
GB201303685D0 (en) Cyclosporin derivatives